Hematopoietic stem cell transplantation in inborn errors of metabolism—a retrospective analysis on behalf of the pediatric disease working party from the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy
- 26 January 2025
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (4) , 474-481
Abstract
Hematopoietic stem cell transplantation (HSCT) is an established treatment for selected patients with inborn errors of metabolism. In this first report from the PDWP-SBTMO, we included 105 patients transplanted between 1988 and 2021 across six Brazilian HSCT centers. The most prevalent diseases were X-linked adrenoleukodystrophy (n = 61) and mucopolysaccharidosis (type I n = 20; type II n = 10), with a median age at HSCT of 8.7 years and 2.1 years, respectively. Most conditioning regimens were myeloablative and busulfan-based. With a median follow-up of 6.7 years, the 5-years overall survival (OS) was 75% (95% CI, 0.65–0.82) with a superior 5-years OS for those transplanted after 2010 (87% vs. 63%, p = 0.01). Higher risk of death was associated with the use of haploidentical donor (HR8.86, p 0.021), unrelated cord blood (HR 8.76, p 0.005), unrelated donor (HR 5.91, p 0.02), and for HSCT performed before 2010 (HR 4.16, p = 0.0015). The CI of acute GVHD was 24.8%, while chronic GVHD was 9.5%. Major causes of death were infections (n = 8), GVHD (n = 6), and neurologic progression (n = 3). Despite improvements in transplant outcomes since 2011, challenges persist, emphasizing the need for early diagnosis, timely transplantation and expanding HSCT centers with expertise in the field.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- MRI surveillance of boys with X‐linked adrenoleukodystrophy identified by newborn screening: Meta‐analysis and consensus guidelinesJournal of Inherited Metabolic Disease, 2020
- Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter's Hope Leukodystrophy Care NetworkTransplantation and Cellular Therapy, 2019
- Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and FutureTransplantation and Cellular Therapy, 2019
- A report on state‐wide implementation of newborn screening for X‐linked AdrenoleukodystrophyAmerican Journal of Medical Genetics Part A, 2019
- Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2019
- Long-Term Functional Outcomes after Hematopoietic Stem Cell Transplant for Early Infantile Krabbe DiseaseTransplantation and Cellular Therapy, 2018
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less ToxicityTransplantation and Cellular Therapy, 2014
- Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of MetabolismTransplantation and Cellular Therapy, 2012
- Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolismEuropean Journal of Pediatrics, 1997